News and Trends 14 Feb 2023Minoryx Therapeutics announces X-linked adrenoleukodystrophy data Minoryx Therapeutics has announced that data from its phase 2/3 ADVANCE clinical trial of lead candidate, leriglitazone, has been published… February 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023Active Biotech trial confirms eye treatment safety Active Biotech has announced the completion of the phase I clinical study testing the safety and tolerability of its newly-developed… January 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023Biotech in Asia: looking forward to 2023 Masahiko Hayakawa, head of targeted protein degradation at Astellas Pharma Inc., gives us some insights into the state of the… January 11, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022Affibody signs €20 million loan agreement Affibody Medical AB has received a €20 million ($21.2 million) venture debt loan facility from the European Investment Bank, EIB,… December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022Ascletis announces positive COVID-19 trial results Ascletis Pharma Inc. has announced positive topline results from its phase I multiple ascending dose (MAD) study in healthy subjects… December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022Centogene launches rare and neurodegenerative disease Biodata Network German company, Centogene N.V., today (November 4) announced its launch of Biodata Network, a portfolio of data-driven partnering solutions including… November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2022Rila Therapeutics exits stealth mode to address renal fibrosis Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, has emerged from… October 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022FDA fast tracks Immutep non-small cell lung cancer candidate Immutep Limited says the United States Food and Drug Administration (FDA) has granted fast track designation to eftilagimod alpha (efti… October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022OncoSec slashing staff numbers to prioritize pipeline OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding… October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies TrialSpark has announced a new partnership with global pharma company Sanofi to explore novel methods of bringing new treatments to… October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022Spinoff Biohaven launches with $258M and “incredible pipeline” Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric… October 4, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule… October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022Oncopeptides starts European commercialization of myeloma drug in Germany Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in Germany. It marks the first… October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022FDA clears Kira Pharmaceuticals’ phase 2 trial for SLE-TMA treatment Kira Pharmaceuticals says the US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for KP104,… October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022Poxel granted orphan drug designation for kidney disease treatment French biopharma company Poxel SA says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to… October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on… October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2022Treatment for hot flushes and night sweats accepted for regulatory review by EMA A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory… September 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022Australian Agilex Biolabs expands its capacity with new toxicology testing facility A toxicology facility with more than 10,000 sq ft of laboratory space has opened in Australia and will help Agilex… September 26, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies… September 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2022Palisade Bio announces closing of $13.8M upsized underwritten public offering A biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications has announced today (August 17) the closing of… August 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email